Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: Experience with 27 patients

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 7, 2015, Pages 404-408

  Zinzani, Pier Luigi ^a   Vitolo, Umberto ^b   Viviani, Simonetta ^c   Corradini, Paolo ^c   Motta, Giovanna ^d   Tani, Monica ^e   Cascavilla, Nicola ^f   Hohaus, Stefan ^g   Merli, Francesco ^h   Argnani, Lisa ^a   Broccoli, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Bendamustine; Brentuximab vedotin; Hodgkin's lymphoma; Refractory; Relapsed

Indexed keywords

BENDAMUSTINE; BRENTUXIMAB VEDOTIN; ALKYLATING AGENT; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; TREATMENT FAILURE; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BENDAMUSTINE HYDROCHLORIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84937516543     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.023     Document Type: Article

References (26)

1. L. Holmberg, and D.G. Maloney The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma J Natl Compr Canc Netw 9 2011 1060 1071
2. K. Bauer, N. Skoetz, I. Monsef, and et al. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma Cochrane Database Syst Rev 8 2011 CD007941
3. D.C. Linch, D. Winfield, A.H. Goldstone, and et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Lancet 341 1993 1051 1054
4. N. Schmitz, B. Pfistner, M. Sextro, and et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Lancet 359 2002 2065 2071
5. M. Andre, M. Henry-Amar, J.L. Pico, and et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study J Clin Oncol 17 1999 222 229
6. P. Brice Managing relapsed and refractory Hodgkin lymphoma Br J Haematol 141 2008 3 13
7. J. Kuruvilla, A. Keating, and M. Crump How I treat relapsed and refractory Hodgkin lymphoma Blood 117 2011 4208 4217
8. A. Younes, A.K. Gopal, S.E. Smith, and et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma J Clin Oncol 30 2012 2183 2189
9. + hematologic malignancies: the German Hodgkin Study Group experience Blood 120 2012 1470 1472
10. + lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre Haematologica 98 2013 611 614
11. P.L. Zinzani, S. Viviani, A. Anastasia, and et al. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily practice outside clinical trials Haematologica 98 2013 1232 1236
12. A. Salihoglu, T. Elverdi, I. Karadogan, and et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey Ann Hematol 94 2015 415 420
13. D. Kahraman, S. Theurich, A. Rothe, and et al. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma Leuk Lymphoma 55 2014 811 816
14. M. Mian, M. Farsad, N. Pescosta, and et al. Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation Ann Hematol 92 2013 121 123
15. F. Magyari, Z. Simon, S. Barna, and et al. Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation Hematol Oncol 30 2012 98 100
16. A.J. Moskowitz, P.A. Hamlin Jr., M.A. Perales, and et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma J Clin Oncol 31 2013 456 460
17. G. Corazzelli, F. Angrilli, A. D'Arco, and et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma Br J Haematol 160 2013 207 215
18. H. Ghesquières, A. Stamatoullas, O. Casasnovas, and et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients Leuk Lymphoma 54 2013 2399 2404
19. A. Anastasia, C. Carlo-Stella, P. Corradini, and et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi Br J Haematol 166 2014 140 153
20. B.D. Cheson, B. Pfistner, M.E. Juweid, and et al. Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
21. A. Biggi, A. Gallamini, S. Chauvie, and et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers J Nucl Med 54 2013 683 690
22. J.A. Francisco, C.G. Cerveny, D.L. Meyer, and et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102 2003 1458 1465
23. S.O. Doronina, B.E. Toki, M.Y. Torgov, and et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat Biotechnol 21 2003 778 784
24. L.M. Leoni, and J.A. Hartley Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity Semin Hematol 48 2011 S12 S23
25. P.L. Zinzani, E. Derenzini, C. Pellegrini, and et al. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin Br J Haematol 163 2013 681 683
26. A. LaCasce, A. Sawas, R.G. Bociek, and et al. A phase 1/2 single-arm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma in the first salvage setting: interim results Biol Blood Marrow Transplant 20 suppl 2014 S161